Recent news highlights PMI’s Q2 2026 earnings results, operational performance, and strategic developments in smoke-free products.

• Philip Morris International held its Q2 2026 earnings call highlighting operational and financial results [N1].
• The company reported organic sales growth of 7.6% year-over-year in Q2 2026, driven by smoke-free product volumes [N2].
• Key metrics from Q2 2026 earnings showed favorable pricing and volume/mix effects, with net revenues increasing 10.4% year-over-year for the quarter [N3].
• PMI’s strong performance in international smoke-free and combustibles segments was noted in Q2 2026 results [N4].
• Despite a decline in Q2 2026 earnings, PMI maintained its full-year 2026 adjusted EPS outlook excluding foreign exchange impacts [N5].
• The Q2 2026 earnings conference call was held on July 22, 2026, at 9:00 AM ET [N6].
• Pre-market reports ahead of Q2 2026 earnings noted PMI among companies releasing results on July 22, 2026 [N7].
• Prior to Q2 2026 earnings, market commentary discussed PMI’s operational performance and smoke-free business growth [N8].

Philip Morris International’s transition towards smoke-free products, supported by substantial R&D investment and regulatory authorizations, positions it to capture growth in reduced-risk nicotine products. The company’s acquisition of Swedish Match expanded its oral nicotine offerings globally. PMI’s broad geographic footprint and strong brand recognition in both combustible and smoke-free segments provide multiple revenue streams. The company’s wellness unit, Aspeya, offers potential for diversification into consumer wellness products, including cannabinoid-based offerings, aligning with evolving consumer preferences.

Philip Morris International faces risks from regulatory changes that could restrict product marketing, flavor availability, or adult consumer access to information about smoke-free products. Competitive pressures from established tobacco companies, new market entrants, and illicit trade may impact market share and profitability. Supply chain dependencies, including reliance on third-party manufacturers and suppliers for electronic devices and tobacco leaf, pose operational risks. Geopolitical factors, currency exchange controls, and economic conditions in key markets may adversely affect financial performance. Impairments and restructuring charges have impacted recent earnings.

Philip Morris International’s moat is supported by its strong global brand portfolio, including Marlboro, the world’s best-selling international cigarette brand, and its leading smoke-free product brands IQOS, ZYN, and VEEV. The company’s significant investment in scientific research and development, including over $16 billion since 2008, underpins its innovation in smoke-free products and regulatory approvals such as FDA Modified Risk Tobacco Product authorizations. PMI’s extensive global distribution network and market presence in approximately 170 markets for cigarettes and over 100 markets for smoke-free products provide scale advantages. The company’s diversified product portfolio across combustible and smoke-free categories and its evolving organizational structure enhance its competitive positioning.

• Regulatory Risks: Changes in tobacco and nicotine product regulations, including restrictions on marketing, flavors, and product claims, could adversely affect PMI’s ability to commercialize and differentiate its products.
• Competitive Risks: PMI faces competition from other tobacco companies, new entrants in smoke-free products, and illicit trade, which may erode market share and profitability.
• Supply Chain Risks: Dependence on third-party manufacturers and suppliers, including for electronic components and tobacco leaf, may lead to disruptions affecting product availability and quality.
• Geopolitical and Currency Risks: Operations in multiple jurisdictions expose PMI to currency exchange controls, devaluation risks, and geopolitical uncertainties that may impact financial results.
• Impairment and Restructuring Risks: PMI has recorded impairment charges and restructuring costs related to business realignments and investments, which may continue to affect earnings.

• Philip Morris International Inc. is a Virginia holding company incorporated in 1987 and publicly listed on the NYSE since 2008.
• The company is a leading international consumer goods company focused on delivering a smoke-free future, evolving its portfolio to include products outside tobacco and nicotine sectors.
• Its product portfolio primarily consists of cigarettes and smoke-free products including heat-not-burn, nicotine pouch, and e-vapor products.
• Since 2008, PMI invested over $16 billion in developing and commercializing smoke-free products, including scientific assessment capabilities.
• In November 2022, PMI acquired Swedish Match AB, a leader in oral nicotine delivery, combining IQOS and ZYN brands globally.
• PMI holds full rights to commercialize IQOS in the U.S. as of April 30, 2024, after ending its U.S. commercial relationship with Altria Group in 2022.
• The FDA authorized marketing of Swedish Match’s General snus, ZYN nicotine pouches, and versions of PMI’s IQOS devices and consumables, including Modified Risk Tobacco Product (MRTP) authorizations.
• PMI’s smoke-free business (SFB) includes smoke-free products, wellness products, and consumer accessories like lighters and matches.
• Smoke-free products (SFPs) provide nicotine without combusting tobacco, including heat-not-burn, e-vapor, and oral smokeless products, generating far lower levels of harmful chemicals.
• PMI’s leading SFP brands are IQOS, ZYN, and VEEV, available in 109 markets as of June 30, 2026.
• Cigarettes are sold in approximately 170 markets, often holding number one or two market share positions; Marlboro is the leading international cigarette brand accounting for about 43% of cigarette shipment volume in 2025.
• PMI’s shipment volume in 2025 included 786.5 billion equivalent units: 607.4 billion cigarettes and 179.1 billion smoke-free products (HTU, oral SFP, e-vapor).
• PMI’s business is organized into three reportable segments as of 2026: International Smoke-Free, International Combustibles, and U.S. (including wellness unit Aspeya).
• The wellness unit Aspeya focuses on oral consumer wellness offerings including medical and non-recreational cannabinoid products, with negligible near- to medium-term revenue from cannabinoids.
• PMI’s net revenues for the six months ended June 30, 2026, were $21.3 billion, a 9.8% increase from the prior year period, driven by favorable pricing and volume/mix in international smoke-free and combustibles segments.
• For the three months ended June 30, 2026, net revenues were $11.2 billion, a 10.4% increase year-over-year, with smoke-free volumes growing 7.5% and total shipment volume increasing 2.5%.
• Net earnings attributable to PMI for the three months ended June 30, 2026, were $2.8 billion, a 7.3% decrease compared to the prior year period, with diluted EPS of $1.80, down 7.7%.
• PMI recorded a non-cash impairment charge of $511 million related to its RBH equity investment in Q2 2026.
• Liquidity as of June 30, 2026, included cash and cash equivalents of $6.0 billion, current assets of $26.0 billion, current liabilities of $26.5 billion, with a current ratio of 0.98 and cash ratio of 0.23.
• PMI depends on dividends and debt repayments from subsidiaries as primary sources of funds for dividends and debt payments; subsidiaries are generally not limited by long-term debt or other agreements in their ability to pay dividends.
• PMI faces risks from regulatory changes, competitive pressures including from new market entrants and illicit trade, supply chain dependencies, currency exchange controls, and geopolitical factors.
• PMI’s supply chain includes tobacco leaf sourced globally, with direct contracts with farmers representing about 23% of global leaf requirements in 2025.
• PMI’s marketing, administration, and research costs include marketing and selling expenses, general and administrative expenses, and costs to develop new products.
• PMI’s competitive environment is influenced by product quality, brand recognition, innovation, pricing, and regulatory environment.
• PMI’s distribution includes direct sales, independent distributors, zonified exclusive distributors, wholesalers, e-commerce, and brand retail infrastructure.
• PMI’s financial disclosures include detailed segment reporting by product category and geography, with operating income and net revenues disclosed for International Smoke-Free, International Combustibles, and U.S. segments.